HAL (France)open access
Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction
Denosumab, Bone Metastases, Non-Small Cell Lung Cancer Bone Metastases Immune Checkpoint Inhibitors Dissociated Response Denosumab, Dissociated Response, Non-Small Cell Lung Cancer, Immune Checkpoint Inhibitors, 0
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 1079630
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.